Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
87.34 USD | -1.43% | +3.84% | -9.42% |
Financials (USD)
Sales 2024 * | 2.76B | Sales 2025 * | 3.15B | Capitalization | 16.48B |
---|---|---|---|---|---|
Net income 2024 * | 322M | Net income 2025 * | 493M | EV / Sales 2024 * | 5.61 x |
Net cash position 2024 * | 973M | Net cash position 2025 * | 1.35B | EV / Sales 2025 * | 4.81 x |
P/E ratio 2024 * |
52.9
x | P/E ratio 2025 * |
33.5
x | Employees | 3,401 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.32% |
Latest transcript on BioMarin Pharmaceutical Inc.
1 day | -1.43% | ||
1 week | +3.84% | ||
Current month | +1.23% | ||
1 month | -1.20% | ||
3 months | -10.08% | ||
6 months | -2.14% | ||
Current year | -9.42% |
Managers | Title | Age | Since |
---|---|---|---|
Alexander Hardy
CEO | Chief Executive Officer | 56 | Nov. 30 |
Brian Mueller
DFI | Director of Finance/CFO | 50 | 02-11-30 |
Kevin Eggan
CTO | Chief Tech/Sci/R&D Officer | - | 20-10-04 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Pyott
BRD | Director/Board Member | 70 | 16-01-03 |
Director/Board Member | 70 | 05-05-15 | |
Randy Meier
CHM | Chairman | 65 | 06-12-13 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
3.45% | 1 M€ | -.--% | - | |
1.79% | 0 M€ | 0.00% | - | |
1.59% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 87.34 | -1.43% | 1,027,708 |
24-03-27 | 88.61 | +0.99% | 1,031,697 |
24-03-26 | 87.74 | +1.41% | 1,346,939 |
24-03-25 | 86.52 | +1.63% | 1,409,254 |
24-03-22 | 85.13 | +1.21% | 876,820 |
Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.42% | 16.48B | |
+0.44% | 90.78B | |
+9.61% | 43.96B | |
-16.67% | 31.34B | |
+44.99% | 23.45B | |
-25.92% | 15.03B | |
-9.27% | 12.79B | |
-7.57% | 12.19B | |
+0.07% | 8.5B | |
-11.81% | 7.82B |